Proprietary AI analyst is now available
- Public Comps
- Caribou Biosciences
Caribou Biosciences Valuation Multiples
Discover Caribou Biosciences' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Innate Pharma, BioInvent International, Karolinska Development, PhotoCure and more.
Caribou Biosciences Overview
About Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Founded
2011
HQ

Employees
147
Website
Financials (LTM)
EV
$76M
Valuation Multiples
Start free trialCaribou Biosciences Financials
Caribou Biosciences reported last 12-month revenue of $18M and negative EBITDA of ($143M).
In the same LTM period, Caribou Biosciences generated $18M in gross profit, ($143M) in EBITDA losses, and had net loss of ($137M).
Revenue (LTM)
Caribou Biosciences P&L
In the most recent fiscal year, Caribou Biosciences reported revenue of $11M and EBITDA of ($133M).
Caribou Biosciences is unprofitable as of last fiscal year, with EBITDA margin of (1188%) and net margin of (1327%).
Financial data powered by Morningstar, Inc.
Caribou Biosciences Stock Performance
Caribou Biosciences has current market cap of $167M, and enterprise value of $76M.
Market Cap Evolution
Caribou Biosciences' stock price is $1.68.
Caribou Biosciences share price decreased by 28.8% in the last 30 days, and increased by 33.5% in the last year.
Caribou Biosciences has an EPS (earnings per share) of $-1.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $76M | $167M | 0.0% | -28.8% | -11.6% | 33.5% | $-1.49 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCaribou Biosciences Valuation Multiples
Caribou Biosciences trades at 4.1x EV/Revenue multiple, and (0.5x) EV/EBITDA.
EV / Revenue (LTM)
Caribou Biosciences Financial Valuation Multiples
As of June 29, 2026, Caribou Biosciences has market cap of $167M and EV of $76M.
Caribou Biosciences has a P/E ratio of (1.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Caribou Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Caribou Biosciences Margins & Growth Rates
Caribou Biosciences grew revenue by 130% and EBITDA by 15% in the last fiscal year.
In the most recent fiscal year, Caribou Biosciences reported EBITDA margin of (1188%) and net margin of (1327%).
Caribou Biosciences Margins
Caribou Biosciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Caribou Biosciences Operational KPIs
Caribou Biosciences' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Caribou Biosciences' Rule of 40 is (467%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Caribou Biosciences' Rule of X is (272%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Caribou Biosciences Competitors
Caribou Biosciences competitors include Innate Pharma, BioInvent International, Karolinska Development, PhotoCure, Acumen Pharmaceuticals, Biomm, Corbus Pharmaceuticals, ProQR Therapeutics, Panion & Bf Biotech and NRX Pharmaceuticals.
Most Caribou Biosciences public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 14.9x | 6.8x | (4.7x) | 3.9x | |||
| 4.7x | 5.1x | (3.6x) | (2.6x) | |||
| - | - | - | - | |||
| 2.5x | 2.3x | 23.8x | 18.8x | |||
| - | - | (0.6x) | (0.6x) | |||
| 3.4x | - | 72.7x | - | |||
| - | 30.3x | (0.3x) | - | |||
| 4.7x | 5.2x | (2.0x) | (1.4x) | |||
This data is available for Pro users. Sign up to see all Caribou Biosciences competitors and their valuation data. Start Free Trial | ||||||
Caribou Biosciences VC Funding History
Before going public, Caribou Biosciences raised $168M in total equity funding, across 4 rounds.
Caribou Biosciences Funding Rounds
Investments by Caribou Biosciences
Caribou Biosciences has invested in 1 company to date.
Latest investment by Caribou Biosciences was on November 18th 2014. Caribou Biosciences invested in Intellia Therapeutics in their $15M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Caribou Biosciences
| Description | Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
| HQ Country | |
| HQ City | - |
| Deal Date | 18 Nov 2014 |
| Round | Series A |
| Raised | $15M |
| Investors | Caribou Biosciences; Novartis; Atlas Venture |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Caribou Biosciences investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Caribou Biosciences
| When was Caribou Biosciences founded? | Caribou Biosciences was founded in 2011. |
| Where is Caribou Biosciences headquartered? | Caribou Biosciences is headquartered in United States. |
| How many employees does Caribou Biosciences have? | As of today, Caribou Biosciences has over 147 employees. |
| Who is the CEO of Caribou Biosciences? | Caribou Biosciences' CEO is Rachel Haurwitz. |
| Is Caribou Biosciences publicly listed? | Yes, Caribou Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Caribou Biosciences? | Caribou Biosciences trades under CRBU ticker. |
| When did Caribou Biosciences go public? | Caribou Biosciences went public in 2021. |
| Who are competitors of Caribou Biosciences? | Caribou Biosciences main competitors include Innate Pharma, BioInvent International, Karolinska Development, PhotoCure, Acumen Pharmaceuticals, Biomm, Corbus Pharmaceuticals, ProQR Therapeutics, Panion & Bf Biotech, NRX Pharmaceuticals. |
| What is the current market cap of Caribou Biosciences? | Caribou Biosciences' current market cap is $167M. |
| What is the current revenue of Caribou Biosciences? | Caribou Biosciences' last 12 months revenue is $18M. |
| What is the current revenue growth of Caribou Biosciences? | Caribou Biosciences revenue growth (NTM/LTM) is 52%. |
| What is the current EV/Revenue multiple of Caribou Biosciences? | Current revenue multiple of Caribou Biosciences is 4.1x. |
| Is Caribou Biosciences profitable? | No, Caribou Biosciences is not profitable. |
| What is the current EBITDA of Caribou Biosciences? | Caribou Biosciences has negative EBITDA and is not profitable. |
| What is Caribou Biosciences' EBITDA margin? | Caribou Biosciences' last 12 months EBITDA margin is (779%). |
| What is the current EV/EBITDA multiple of Caribou Biosciences? | Current EBITDA multiple of Caribou Biosciences is (0.5x). |
| How many companies Caribou Biosciences has acquired to date? | Caribou Biosciences hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Caribou Biosciences has invested to date? | As of June 2026, Caribou Biosciences has invested in 1 company. |
| What was the last Caribou Biosciences investment? | On 18th November 2014 Caribou Biosciences invested in Intellia Therapeutics, participating in a $15M Series A round, alongside Novartis and Atlas Venture. |
| In what companies Caribou Biosciences invested in? | Caribou Biosciences invested in Intellia Therapeutics. |
See public comps similar to Caribou Biosciences
Lists including Caribou Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
